Kymera Therapeutics, Inc.

NASDAQ:KYMR

Biotechnology

Healthcare
$119.39 +1.67%

+$1.50 today

Market cap
$10.19B
Beta
2.03
P/E (TTM)
-28.3
EPS (TTM)
-$3.23
52W Low $36.65High $103.00

Volume 0.72M

Average 0.58M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$232.89M

FY 2025 · Annual

Investing Cash Flow

-$521.06M

FY 2025 · Annual

Financing Cash Flow

$990.71M

FY 2025 · Annual

+62.7% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(100.22M)(154.81M)(146.96M)(223.86M)(311.35M)
Depreciation & Amortization2.4M2.98M3.57M7.37M8.31M
Deferred Income Tax00000
Stock-Based Compensation24.97M35.48M43.12M55.01M59.9M
Change in Working Capital(61.92M)(37.62M)9.25M(23.97M)15.27M
Accounts Receivables577K(2.4M)(16.23M)17.82M947K
Inventory8.71M2.4M000
Accounts Payables54K253K0(307K)(1.97M)
Other Working Capital(71.26M)(37.88M)25.48M(41.48M)16.29M
Other Non-Cash Items5.83M889K(11.8M)(9.06M)(5.02M)
Operating Cash Flow(128.95M)(153.09M)(102.83M)(194.5M)(232.89M)
Capital Expenditures(1.6M)(2.84M)(34.48M)(12.84M)(1.45M)
Acquisitions (Net)5.81M(20.52M)000
Purchases of Investments(456.4M)(445.97M)0(901.23M)(1.01B)
Sales of Investments358.17M469.33M0496M479.14M
Other Investing Activities(5.81M)20.52M174.37M13.98M8.88M
Investing Cash Flow(99.84M)20.52M139.89M(404.08M)(521.06M)
Debt Repayment(849K)(1.13M)(76K)(1.58M)(1.49M)
Common Stock Issued243.11M149.83M0596.62M992.21M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities8.02M4.3M4.27M13.81M0
Financing Cash Flow250.28M153M4.19M608.85M990.71M
Effect of Forex Changes00000
Net Change in Cash21.5M20.43M41.25M10.27M236.76M
Free Cash Flow(130.54M)(155.92M)(137.31M)(207.34M)(234.34M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$311.4M
+ D&A$8.3M
+ Stock-Based Comp$59.9M
+ Deferred Tax$0
+ Working Capital$15.3M
- Other Non-Cash-$5.0M
= Operating Cash Flow-$232.9M
- Capex-$1.4M
= Free Cash Flow-$234.3M

Analysis

FY2025 free cash flow is -$234.3M. FCF conversion is 75.3% of net income. Operating cash flow was -$232.9M, with capex of -$1.4M. The largest bridge item is Stock-Based Comp at $59.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportOct 29, 2026
10-QQuarterly reportOct 29, 2026
SC 13G/ASC 13G/A filingOct 27, 2026
4Statement of changes in beneficial ownershipOct 1, 2026
SC 13G/ASC 13G/A filingSep 8, 2026

Does KYMR generate free cash flow?

Kymera Therapeutics, Inc. (KYMR) generated -$234.34M of free cash flow in fiscal 2025.

How much operating cash flow does KYMR produce?

Operating cash flow was -$232.89M, before capital expenditures of $1.45M.